Bringing The Next-Generation Of Antibiotics
to win the war against resistant bacteria
Our Vision
Our company
Omnix Medical is a biopharmaceutical company
Founded in 2015, Omnix Medical is developing an arsenal of novel antibiotic agents for the treatment of infections involving drug-resistant bacteria.
Omnix’s technology can tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.
Our technology
Our exceptional technology offers a first-in-its-class drug
Company News
STUDY: In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii
The rapid worldwide spread of antimicrobial resistance (AMR) underscores the significant need for the development of innovative treatments to fight multidrug-resistant bacteria. Our Scientists at Omnix
OMNIX MEDICAL ANNOUNCES THE ADDITION OF TWO NEW PEPTIDE FAMILIES – OMN50 AND OMN70
Omnix Medical is pleased to announce the addition of two new peptide families – OMN50 and OMN70. At Omnix, we are working hard to build
OMNIX MEDICAL STARTS PHASE I CLINICAL TRIAL OF NOVEL ANTI-INFECTIVE; FIRST HEALTHY VOLUNTEERS DOSED
New mechanism of action (MoA) addressing global increase of antimicrobial resistance (AMR) burden and shortage of potent anti-infectives JERUSALEM, Israel, April 12, 2022 — Omnix
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).